• Channels
    • All News
    • Premium Content
    • In Focus
    • Special
    • AI
    • Bioregnum
    • Biotech Voices
    • Cell/Gene Tx
    • China
    • Coronavirus
    • Deals
    • Diagnostics
    • Discovery
    • FDA+
    • Financing
    • Law
    • Letters to the Editor
    • Manufacturing
    • Marketing
    • Opinion
    • Outsourcing
    • Peer Review
    • People
    • Pharma
    • R&D
    • Startups
    • Weekly
  • Webinars
  • Biopharma Jobs
  • More
    • Work at Endpoints
    • Letter to Editors
    • IPO Tracker
    • Webinars
    • Events
    • Sponsored Posts
    • Advertise
    • Privacy Policy
    • Endpoints Merch
    • About Us
    • Help
  • SIGN UP

PPD Biotech pan­el: Five biotech lead­ers of­fer their sur­pris­ing takes on the big trends shap­ing the in­dus­try in the Bay Area and be­yond

5 years ago

A Swedish biotech is tar­get­ing throm­bo­sis us­ing the body's own de­fense sys­tem to pre­vent blood clots with low­er risk of bleed­ing as­so­ci­at­ed with cur­rent an­tithrom­bot­ic ther­a­pies

5 years ago

The first FDA-ap­proved dig­i­tal pill — what it means for phar­ma

5 years ago

Is the phar­ma busi­ness mod­el ready for pre­ci­sion med­i­cine?

5 years ago

PPD Biotech pan­el: Five lead­ers in the Boston hub eval­u­ate the top trends — and where we’re all head­ed in the next 5 years

5 years ago

Bio­phar­ma­ceu­ti­cal Deal­mak­ers’ In­ten­tions in 2018: Sup­ply and De­mand Ex­pec­ta­tions and Im­bal­ances

5 years ago

Swedish Biotech Dex­Tech Med­ical shoots for bil­lion dol­lar prostate can­cer mar­ket — con­cludes phI­Ib study ear­ly

5 years ago

Bio­phar­ma­ceu­ti­cal Deal­mak­ers’ In­ten­tions in 2018: Bull­ish Run to Con­tin­ue Amidst Signs of Greater Risk Aver­sion

5 years ago

Min­i­mal Resid­ual Dis­ease: A Prog­nos­tic Fac­tor Mov­ing the Nee­dle in Pa­tient Care

5 years ago

For­get about greed, Pres­i­dent Trump: the vil­lain re­spon­si­ble for high drug prices is in­ef­fi­cien­cy

5 years ago

The Evolv­ing Over­all Sur­vival Ex­pec­ta­tions of Pa­tients with Re­lapsed or Re­frac­to­ry Mul­ti­ple Myelo­ma

5 years ago

The win­ners and losers of the Swedish biotech in­dus­try IPO fren­zy

5 years ago

How as­set sup­ply and de­mand is shap­ing bio­phar­ma­ceu­ti­cal deal­mak­ing

6 years ago

Bio­phar­ma­ceu­ti­cal Deal­mak­ers’ In­ten­tions in 2017: In­flu­ences and Hot Spots

6 years ago

CVS Leads Trend To­ward Less Ex­pen­sive Neu­trope­nia Treat­ments

7 years ago
First page Previous page 4567
Endpoints News

Bioscience & Technology Business Center
The University of Kansas
Lawrence, Kansas

Latest

  • All News
  • Premium Content
  • Don't Miss
  • Special
  • In Focus

Channels

  • AI
  • Bioregnum
  • Biotech Voices
  • Cell/Gene Tx
  • China
  • Coronavirus
  • Deals
  • Diagnostics
  • Discovery
  • FDA+
  • Financing
  • Law
  • Letters to the Editor
  • Manufacturing
  • Marketing
  • Opinion
  • Outsourcing
  • Peer Review
  • People
  • Pharma
  • R&D
  • Startups
  • Weekly

More

  • Work at Endpoints
  • Letter to Editors
  • IPO Tracker
  • Events
  • Webinars
  • Sponsored Posts
  • Advertise
  • Endpoints Merch
  • About Us
  • Help

Work in biotech

  • Endpoints Careers

© Endpoints Company 2023

  • Help
  • Advertise
  • Privacy Policy
  • Business Model
Endpoints News

Log in to your account

e-mail

password

Endpoints News

request magic link

If you're already an Endpoints subscriber, enter your email below for a magic link that lets you log in quickly without using a password. Please note the magic link is one-time use only and expires after 24 hours.

email

Endpoints News

reset password

We'll e-mail you a link to set a new password. Please note this link is one-time use only and is valid for only 24 hours.

email

Endpoints News

About You

Subscriptions

ENDPOINTS NEWS Daily at 11:30 AM ET

EARLY EDITION Daily at 7:15 AM ET

ENDPOINTS PHARMA Daily at 2 PM ET

ENDPOINTS MARKETING RX Tue at 2 PM ET

ENDPOINTS FDA+ Wed at 2 PM ET

ENDPOINTS MANUFACTURING Thu at 2 PM ET

ENDPOINTS WEEKLY Sat at 6 AM ET